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Chemotherapy, autologous hematopoietic cell
transplantation (HCT), and allogeneic HCT are the
3 major forms of therapy available to the patient with
acute leukemia. A major challenge facing the physician
caring for the patient with acute leukemia is selecting
the right approach at the right time. Recent progress
in the development of diagnostic techniques that pro-
vide valuable prognostic information, as well as ad-
vances in each of the 3 major forms of therapy, have
resulted in substantial changes in recommendations
about who should be transplanted, when the transplant
should be performed, and which form of transplanta-
tion is preferable. The following 3 sections provide
a brief review of this general topic for pediatric acute
leukemia, adult lymphoblastic leukemia (ALL), and
adult acute myelogenous leukemia (AML).
INDICATIONS FOR TRANSPLANTATION IN CHILDHOOD
LEUKEMIA
Introduction
More than 80% of children with ALL are now
cured with chemotherapy without need for transplan-
tation. This remarkable progress is the result of serial
large-scale randomized clinical trials incorporating
improvements in risk group assignment, administra-
tion of risk-adjusted therapy, and intensified therapy
for children with high-risk disease [1]. Despite these
advances, significant numbers of children still die of re-
lapsed or refractory ALL, as ALL is the most frequent
malignancy of childhood, and transplantation offers an
important alternative modality of treatment for those
children. Significant progress has also been made in
the treatment of childhood AML, although chemo-
therapy regimens have not been as successful as in154childhood ALL [2-4]. Sibling donor transplantation
remains an essential component of the treatment of
childhood AML, but similar to AML in adults, recent
chemotherapy outcomes now support the limitation
of the use of transplantation in first remission to chil-
dren with intermediate or high-risk disease. Unrelated
donor transplantation is an important component of
treatment of relapsed AML, but is limited by the chal-
lenge of achieving a second remission, particularly in
children with early relapse. Improved HLA typing
techniques and strategies for donor selection mean
that results approaching those seen with matched sib-
ling donors can be achieved with well-matched unre-
lated donor (MUD) stem cells, leading to greater
interest in identifying a role for unrelated donor stem
cell sources for high risk AML cases in first complete
remission (CR1) [5,6].
Transplantation for Children with (ALL)
Transplant for ALL in first remission. Many case
series of HCT for ALL in CR1 have been published
over the years. Overall, the majority of studies show
at least a moderate reduction in relapse rate with
transplantation compared with chemotherapy, but
with increased treatment-related mortality (TRM).
Variability in the data from different studies reflects
differences in the definitions used for high-risk ALL
meriting transplantation in CR1. Many of the criteria
used in the past to define high risk (eg, T cell ALL and
mediastinal mass, high white cell count [WCC],
t[4;11]) are no longer associated with markedly
inferior outcomes with modern chemotherapy, and
would not currently be considered an indication for
HCT in CR1. In the United States, Philadelphia
chromosome-positive ALL (Ph1 ALL), low hypo-
diploidy, and the small number of cases with primary
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sidered sufficiently high risk to merit consideration
of transplantation in CR1 using current Children’s
Oncology Group (COG) chemotherapy, and each of
these indications is discussed subsequently [1]. Infants
with ALL provide particular challenges, commonly
presenting with biologically adverse features, altered
drug pharmacokinetics, and vulnerability to infection.
The role of transplant in CR1 for infant ALL is con-
troversial, and is also discussed below.
Ph1 ALL. The low frequency (\4% of cases of
childhood ALL) of Ph1 ALL has limited the identifi-
cation of risk factors and optimal therapy. To try to
circumvent this limitation, Arico0 et al [7] analyzed
pooled data from 326 children and young adults
treated for Ph1 ALL by 10 study groups. The analysis
showed that HCT from a matched sibling donor was
superior to other types of transplantation, and to in-
tensive chemotherapy alone in prolonging initial com-
plete remission. These data support the common
clinical practice of offering HCT in first remission
to children with Ph1 ALL and a matched sibling do-
nor. However, for the majority of children without
a matched sibling donor, there is less clear consensus
on optimum management. Studies reporting outcome
of unrelated donor HCT in these patients, so far show
mixed results [7-9]. Some recent reports have shown
encouraging results for the use of alternate donor
transplant for Ph1 ALL in CR1 [10,11]. Continued
investigation of the role of unrelated donor HCT in
first remission for the children in this poorer prognosis
group is justified. More insight into prognostic factors
will also allow better stratification of patients to help
improve outcomes. Based on current available data
[7,10] unrelated donor transplant should certainly be
considered for children with National Cancer Institute
(NCI) high-risk characteristics. In contrast, children
with NCI good-risk characteristics and no well-
matched sibling or unrelated donor may achieve ac-
ceptable results with chemotherapy [7].
The tyrosine kinase inhibitor imatinib has been
shown to have activity in childhood Ph1 ALL, and
current clinical trials are studying whether chemother-
apy outcomes can be improved by including imatinib
with intensive chemotherapy. It remains important
to follow these studies carefully, as imatinib, or other
newer tyrosine kinase inhibitors, may improve survival
with chemotherapy sufficiently to allow use of trans-
plantation only in second remission (CR2). In addition
to incorporation into chemotherapy regimens, investi-
gators have shown that imatinib is well tolerated when
given prophylactically posttransplantation, although
current follow-up is too short to determine whether
outcomes are improved.
Hypodiploid ALL. Children with severe hypodip-
loidy (\45 chromosomes) have poor outcomes
(\40% survival) with chemotherapy [12]. Most re-cently, Nachman et al [13] reported 139 patients
with ALL and hypodiploidy (\45 chromosomes) and
confirmed poor survival in children with\44 chromo-
somes. However, compared with patients with \44
chromosomes, patients with 44 chromosomes had
a significantly better survival (69%), suggesting that
this group may not merit HCT in first remission.
Twenty-nine children with hypodiploid ALL trans-
planted in first or second remission with a matched sib-
ling donor between 1990 and 2001 have been reported
to the International Bone Marrow Transplant Regis-
try. Three-year survival was 65% (95% confidence in-
terval [CI] 45%-80%), supporting the use of early
HCT in this small subgroup (M. Eapen, personal com-
munication, 2002).
Primary induction failure. A small subset (\2%)
of children with ALL fail to achieve remission after
28 days of induction chemotherapy, and if they do
achieve remission, only 40% will survive, suggesting
that early transplantation might be of benefit. No large
case series are available to accurately assess outcomes
after HCT in these patients, and this is an important
question for future study. It cannot be assumed that
HCT will necessarily cure this small group of children
with a particularly resistant initial disease.
Infant ALL. Molecular rearrangements that in-
volve the MLL gene occur in a high proportion of leu-
kemias arising in infants \1 year of age, most
frequently a t(4;11)(q21;q23) translocation. Prognosis
in MLL-rearranged ALL in infants is generally poor
with current chemotherapy, with generally \20%
5-year event-free survival (EFS) [14-16]. Because of
the poor response to chemotherapy, infants with
MLL-rearranged ALL are often considered as candi-
dates for early transplantation. The Seattle group ana-
lyzed results of 40 infants who received an HCT
between 1982 and 2003 [17]. Three-year disease-free
survival (DFS) was 73% in 14 patients transplanted
in CR1, suggesting early (in CR1) HCT might benefit
these children, as reported by others. In contrast,
Interfant-99 enrolled 482 infants with ALL from
22 countries between 1999 and 2005 [18], and reported
that MLL gene rearrangement, very high WCC (.300
 109/L), age\6 months, and a poor response to the
prednisone prophase were independently associated
with inferior outcomes. However, the 4-year DFS
did not differ significantly between high-risk patients
treated with chemotherapy alone (37.4%) versus
chemotherapy plus HCT (50.2%) when adjusted for
time to transplantation (P 5 .19). There is a clear
need for further prospective studies to define the role
of HCT in infants at high risk for treatment failure.
Such studies will need to be multi-institutional and
possibly multinational, as infant leukemia is rare. Stud-
ies should include evaluation of the late consequences
of therapy in survivors, as morbidity can be significant
in young children.
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majority of children with ALL are considered candi-
dates for transplantation only if they relapse after re-
ceiving chemotherapy. The appropriate use of HCT
or chemotherapy alone for children with relapsed
ALL remains a controversial topic. A number of co-
operative groups, including COG, have attempted
to compare outcomes of transplant and chemother-
apy in randomized studies and have been unsuccess-
ful, largely because of lack of acceptance of
randomization by either or both physicians and par-
ents. In the absence of randomized data, the best
available comparison comes from registry analyses.
Eapen et al [19] compared 188 patients enrolled in
Pediatric Oncology Group chemotherapy trials and
186 children who received HLA-matched sibling
transplants between 1991 and 1997. For children
with early first relapse (\36 months from diagnosis),
risk of a second relapse was significantly lower after
transplant with a total-body irradiation (TBI) regi-
men (relative risk [RR], 0.49; 95% CI 0.33-0.71,
P\ .001) than chemotherapy treatment, and leuke-
mia-free survival (LFS) was improved. In contrast,
transplant in CR2 did not offer an advantage over
chemotherapy for children with a late relapse ($36
months; P 5 .78).
The Italian Bone Marrow Transplant group re-
ported on 57 children who received allogeneic trans-
plant for ALL in CR2 and compared them to 230
patients who received chemotherapy following their
relapse [20]. In agreement with the findings of the
Center for International Blood and Marrow Trans-
plant Research (CIBMTR) study, these authors dem-
onstrated that patients who had an early first relapse
(\30 months) had significantly longer DFS following
transplant than treatment with chemotherapy, but this
advantage was lost in patients with a later relapse (.30
months following diagnosis).
The German pediatric cooperative groups (BFM
and COALL) reported 51 children with ALL in
CR2, receiving matched sibling donor transplant
[21]. Comparison of HCT results with outcomes in
children treated with chemotherapy for a bone marrow
relapse showed that patients with an initial remission
longer than 18 months had comparable survival,
whether treated with chemotherapy or bone marrow
transplant. Patients with an early relapse (CR1 \18
months) or a relapse of T-ALL had a minimal chance
of surviving following chemotherapy, and survival
rates were significantly improved by allogeneic HCT.
This data indicates that HCT from a matched
family donor is usually the best option for a child
with early relapse of ALL. Data are currently insuffi-
cient to determine definitively whether similar benefit
can be achieved with alternative donor HCT, al-
though in may centers, results comparable to those
seen with sibling donors can be achieved with an 8-allele MUD, supporting such an approach. The ma-
jority of studies indicate that children with later re-
lapse (generally a CR1 of $36 months) can achieve
similar survival with chemotherapy or with transplant
from a sibling donor, so treatment options for these
children should be discussed carefully with the
family.
Transplantation for Children with AML
Transplantation for AML in first remission.
Matched sibling donor transplant for AML has been
regarded as the optimal postremission therapy for
children with AML for many years. Recent data, how-
ever, show that children with favorable cytogenetics
have outcomes equivalent to those achieved with sib-
ling donor transplant and common practice, and the
current COG study now recommend sibling donor
transplant in CR1 for children with intermediate or
high-risk cytogenetics, with chemotherapy treatment
only for those with favorable cytogenetics (t[8;21];
inv16, t[15;17]). This practice accords with adult
recommendations [22].
Certain subtypes of AML have a notably poor
prognosis with chemotherapy, and transplantation
using sibling donors or unrelated donor stem cell sour-
ces has the potential to improve those outcomes. A ma-
jor limitation to proving or disproving benefit of
transplantation is the small numbers of cases, even in
large national trials. Monosomy 7 or deletion of the
long arm of chromosome 7 (del[7q]) are uncommon
in childhood AML, occurring in only 4% to 5% of
cases. Outcomes have been poor in the majority of
cases, as confirmed in a recent international analysis
of cases pooled from many studies to generate a sam-
ples size large enough to assess risk factors [23]. The
data showed a low likelihood of remission induction
in the monosomy 7 cases (61%) compared with
del(7q) (89%). Transplant did not improve survival
in 77 cases that did achieve remission, but did improve
survival in 17 children transplanted without CR in
whom 31% survived compared with 0% survival in
children who did not achieve CR and were not
transplanted.
Leukemias with FLT3/ITD have a poor prognosis
with chemotherapy treatment. It remains controversial
whether outcomes can be improved with allogeneic
transplantation, and whether this approach holds
more promise than treatment with specific kinase in-
hibitors. A large number of reports have examined
whether killer immunoglobulin-like receptor (KIR)
mismatch can improve disease control in the most
aggressive leukemias, with many positive and many
negative studies. A prospective clinical study in the
COG will seek to address this question in children
with refractory, very poor prognosis, or relapsed
disease.
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Late effects of transplantation in children.
Children with leukemia are vulnerable to late adverse
consequences of therapy, as they are treated at a time
when growth and development are incomplete, and
because they have a potential life expectancy of over
70 years, during which late effects may become appar-
ent. The ‘‘cost of cure’’ using different treatment
modalities might become an important element in
therapeutic choices when differences in survival with
chemotherapy and transplant are not very different.
The use of myeloablative chemotherapy and radiation
certainly has late consequences in children, affecting
growth, endocrine function, risk of secondary cancers,
and in some cases, cognition. Concern about late
toxicities is greatest for those treated as infants. A re-
cent report described health outcomes in 17 children
transplanted for ALL or AML when younger than 3
years of age, between 3.25 and 22.33 years prior to
evaluation in this study [24]. Eleven of the 17 children
had received TBI prior to transplantation. Neuropsy-
chologic testing showed average IQ with attention def-
icits or other weaknesses in most children. Frequent
abnormalities identified included growth hormone de-
ficiency (59%), hypothyroidism (35%), osteochondro-
mas (24%), decreased bone mineral density (24%), and
dyslipidemias (59%). Despite these findings on fo-
cused testing, most subjects were doing well without
major ongoing medical issues. These findings of
good functional outcomes many years after transplant,
even in the youngest children, are in agreement with
the report of Leahey et al [25], who compared late out-
comes of transplant with those seen after chemother-
apy for children with AML. In this report, growth,
renal, and cardiac function were all similar between
the 2 groups, and the only significant difference iden-
tified was that transplanted children were more likely
to need estrogen replacement. Taken together, these
data support treatment selection based on likely sur-
vival, without undue concern for late effects, even in
the youngest children.
INDICATIONS FOR HCT IN ADULTS WITH ALL
Introduction
The cure rate of ALL in adults remains unsatisfac-
tory. The remarkable progress in childhood ALL [1]
over the past 3 decades has not been replicated in adult
ALL with approximately 2/3 of patients under 60 ex-
pected to succumb to their disease and more than
90% of patients over 60 years.
Based on the success in childhood ALL, therapy of
adults has been modeled on a similar therapeutic tem-
plate, consisting of induction, intensification and pro-
longed maintenance therapy.The initial response to induction therapy in ALL is
remarkably high, with 85% to 90% of adults in recent
trials achieving a CR. The response to postremission
chemotherapy is dependent on the prognostic factors
at presentation and the presence of minimal residual
disease (MRD) at the end of induction and intensifica-
tion. The most important prognostic factors at presen-
tation are adverse cytogenetics t(9;22), t(4;11), t(8;14),
a complex karyotype or hypodiploidy/triploidy], age
.35-40 years, and an elevated WCC [26]. The time
taken to achieve a complete remission (4 weeks or
more) may not be as important in adults [27]. Once
in remission, 40% to 50% of young adults (\35-40
years) who do not have adverse prognostic features
can be cured with a standard chemotherapeutic ap-
proach. In contrast, for adults older than 35-40 years,
or those who present with adverse prognostic features,
the cure rate with standard therapy is only in the order
of 15%-20%, depending on the particular subtypes.
HCT
In contrast to AML, historically there has been
a reluctance to use an allogeneic transplantation for
ALL in first remission, based on the success in child-
hood ALL using only chemotherapy, as well as reli-
ance on retrospective registry data [28]; despite the
fact that the clinical importance of graft-versus-leuke-
mia (GVL) has been recognized since 1979 and the ini-
tial reports of GVL in humans were in ALL [29].
Nevertheless, a clear role for allogeneic transplan-
tation has been established for patients at very high
risk, such as those with the Ph1 ALL, as well as other
very high-risk features in CR1, and as for patients with
relapsed or refractory ALL. The notion that allogeneic
transplantation may also be of benefit for patients at
standard risk in CR1 has evolved over the past 15 years.
CR1
The first major study of transplantation for ALL in
first remission was conducted by the French LALA
group, which in 1987, prospectively assigned ALL
patients in CR1 who were \40 years and had an
HLA-matched sibling to an allogeneic bone marrow
transplant (BMT) [30]. All other patients up to age
50 years old were randomized to an autologous trans-
plant versus chemotherapy. Of 116 eligible patients, 92
underwent an allogeneic transplant, with an overall 10-
year survival OS of 46% for the BMT group versus
31% for the control group (P 5 .04). However, a sub-
group analysis confirmed that the difference was only
significant among high-risk patients where the OS
for those undergoing an allogeneic transplantation
was 44% versus 11% of the control patients (P 5
.009). A successor study conducted by the same group
(LALA 94 trial) introduced a risk-adapted approach
stratifying patients according to their prognostic
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transplantation only for high-risk ALL patients.
High-risk patients were defined as those who had
B-lineage ALL with either a WCC of .30  109/L
or adverse cytogenetics including Ph1, t(4;11),
t(1;19) or abnormalities involving 11q 23 rearrange-
ments. Patients with T cell lineage were offered an al-
logeneic transplant if they did not achieve a complete
remission after 1 course of induction. Any patient
with CNS disease at presentation was also considered
at high risk. A significantly improved DFS (45% versus
18%) at 10 years (P 5 .007) was reported for the 100
Ph-negative high-risk patients with a donor compared
to the 159 patients who did not have a donor [31].
Another French study conducted by the GOE-
LAMS group compared sibling allogeneic transplanta-
tion versus delayed autologous transplantation for
similar high-risk patients. Once again, there was a sig-
nificant improvement among the 41 patients undergo-
ing an allogeneic transplantation versus the 106
control patients (P 5 .0027) [32].
At the same time a smaller institutional study from
the Princess Margaret Hospital in Toronto, Canada,
compared 48 ALL patients in CR1 who had a matched
sibling donor versus 39 patients who did not have a do-
nor. All patients in CR1, regardless of risk group, were
offered an allogeneic transplant. For Ph-negative pa-
tients there was no improvement in the EFS or OS
among those undergoing an allogeneic transplantation
[33].
Compared with current major AML studies, all of
these trials in ALL were relatively small and the data
are often difficult to interpret, especially when broken
down by even smaller subgroup analyses.
The International ALL trial, a major transatlantic
collaboration between the Medical Research Council
(MRC) in the United Kingdom and the Eastern Coop-
erative Oncology Group (ECOG) in the United
States, was initiated in 1993 to prospectively define
the role of allogeneic transplants, autologous trans-
plants, and chemotherapy in all adult patients in CR1
up to age 60 years. The CR rate for all 1826 patients
was 91%; it was 93% among Ph-negative patients [27].
Among 915 Ph-negative patients who achieved
a complete remission and in whom a sibling donor
search was initiated, the 5-year OS and EFS were sig-
nificantly improved in the 388 patients who had a do-
nor versus the 527 who did not have a donor (53%
versus 45%; P \ .05). In contrast to other previous
studies, among the 218 patients with standard-risk dis-
ease who had a donor the OS was significantly im-
proved over the 286 who did not have a donor (63%
versus 51% at 5 years; P\ .05) [34].
Despite the reduced relapse rate among all patients
with a donor, the high TRM for high-risk older
patients (39% at 2 years) abrogated the reduction in
the relapse rate such that a definitive advantage couldnot be demonstrated for allogeneic transplants among
the high-risk patients. In this large trial high risk was
defined as any patient over 35 years or those with
a high WCC at presentation. Surprisingly, time to
complete remission was not an independently signifi-
cant variable.
Based on this large trial, the standard of care is
likely to move in favor of offering a sibling allogeneic
transplantation to all ALL patients in CR1 under the
age of 40 years. Although this trial also included
patients \20 years of age, recent data suggest that
teenagers, if treated on standard pediatric protocols,
may have a significantly improved outcome compared
with those treated on adult protocols [35-37].
Whether an allogeneic transplant can further improve
the results in this group of patients remains to be
determined.
The use of MUD transplants for high-risk ALL
patients has not been prospectively evaluated with an
appropriate control group. Nevertheless, the data
from patients with the Philadelphia chromosome sug-
gest that such transplants can be performed with con-
siderable efficacy and toxicity that is not significantly
greater than with sibling allografts [38-40]. Recent re-
ports from the group from Perugia, Italy, suggest that
a haploidentical transplant may be as efficacious as
a MUD transplant for high-risk patients in CR1 [41].
Although these data need to be corroborated by others,
this may be an option for patients who do not have
a sibling or in whom a MUD donor cannot be
identified.
A major collaborative effort between the MRC in
Britain and the major cooperative groups in the United
States is planned to evaluate the role of MUD trans-
plant in Ph-negative patients who are at high risk.
This would comprise patients \40 years who have
either a high WCC at presentation, adverse cytogenet-
ics, or the presence of MRD detected after induction
and intensification.
The predictive value of the presence of MRD has
been confirmed in several studies, both in childhood
and in adult ALL [42,43]. Further studies are needed
to know whether the absence of detectable MRD after
induction or intensification can spare some patients
the need to undergo an allogeneic transplant.
Historically, several studies have evaluated the role
of autologous transplant for ALL in CR1 [44]. It is dif-
ficult to reliably assess the data because of the small
number of patients in these trials and the variability
of study conditions. In general, however, the reported
data suggest that autologous transplant may be at least
as efficacious as standard chemotherapy, and 1 study
reported superiority for high-risk patients [45]. No re-
port suggested that autologous transplantation is infe-
rior to chemotherapy [34]. Very recently, however, the
International ALL study randomized 446 patients in
CR1 to either undergo a single autologous transplant
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apy. In contrast to previous reports, in this large pro-
spective study there was a statistically superior DFS
for patients undergoing chemotherapy [34]. Thus,
outside of a clinical trial, autologous transplantation
cannot be recommended for ALL in CR1.
Relapsed/refractory ALL. Adults with relapsed
ALL have a dismal prognosis with an OS of \10%
at 5 years [45]. Allogeneic transplant provides the
only option of cure for such patients, irrespective of
age or other prognostic factors. Patients who have
not undergone an allogeneic transplant in first remis-
sion and can be successfully induced into a CR2 can
be cured by an allogeneic transplant in 25% of cases
[46]. It is clear that for patients who do not have a re-
lated histocompatible donor a MUD transplant should
be offered. For those patients who do not achieve a sec-
ond remission or those who are refractory to primary
induction an allogeneic transplant is also appropriate,
although the likelihood of a cure in such patients is
\10%. An important issue is whether to attempt rein-
duction therapy or to take such a patient immediately
to transplant. Although the issue is unresolved, it is
likely that the toxicity from the transplant is increased
through reinduction therapy and, thus, it is often rea-
sonable to take a patient directly to the transplant if the
prognostic factors are such that it is unlikely that the
patient will respond to reinduction therapy.
Ph1 ALL. For the past 3 decades the single most
uncontested indication for a sibling allogeneic trans-
plant in any acute leukemia has been a young adult
with Ph1 ALL. The standard of care has evolved
such that these patients have been routinely offered
a MUD donor transplant if a family matched donor
is not available. The data from multiple groups suggest
that somewhere between 35% and 50% of such adults
who had undergone a transplant, from a related or un-
related donor, can be cured. The advent of imatinib
mesylate for patients with Ph1 ALL has altered the
standard of care for these patients [47,48]. Data from
multiple groups have reported that a greater percent-
age of patients can get into CR with imatinib, and
can do this more rapidly. Imatinib also had a major im-
pact on the management of older patients with Ph1
ALL who could not otherwise withstand intensive
therapy.
However, the emerging data to date have not un-
equivocally demonstrated superiority for patients un-
dergoing an allogeneic transplant in the imatinib era
compared with those successfully undergoing an allo-
geneic transplant in CR1 in the pre-imatinib era. More
importantly, perhaps, the remaining issue that needs to
be emphasized is the fact that since the advent of ima-
tinib there has not been a study evaluating the ongoing
imperative for an allogeneic transplant in Ph1 ALL
[49]. If future studies establish the curability of Ph1
patients with intensive chemotherapy and imatinib,without the absolute need for an allogeneic transplant,
this would lead to a complete reversal of standard indi-
cations for an allogeneic transplant in ALL.
Older adults. Probably the most difficult and chal-
lenging current issue in the management of adults with
ALL is to know how to manage patients over the age of
40 years with or without other adverse prognostic fac-
tors. Clearly, these patients are at high risk regardless
of the presence of other recognized adverse prognostic
factors. Althouh the GVL effect in CR1 is very impor-
tant in significantly reducing the rate of relapse, the
problem is that the nonrelapse mortality (NRM) in
this age group may be as high as 40% [34]. Reduced in-
tensity transplant conditioning (RIC) regimen in ALL
is likely to reduce the toxicity in such patients. How-
ever, unlike the emerging data in AML, for ALL there
are insufficient data at the present time to reliably pre-
dict the overall efficacy of this approach. This will be
studied in the prospective international US Inter-
group/MRC trial.
Summary
The overall efficacy of treatment of adult ALL with
chemotherapy seems to have stalled over the past 15
years, with no further significant progress. At the
same time, the role of HCT in ALL is becoming
clearer, although much remains to be learned.
The indications for allogeneic HCT in CR1 are
broadening to include all but teenagers; alternative do-
nors are a viable option for all patients (not only Ph1)
who do not have a family donor, and the enthusiasm
for autologous transplants is waning. The greatest
challenge and uncertainty remains in the management
of older adults with ALL.
INDICATIONS FOR HCT IN ADULT AML
Introduction
AML includes a spectrum of disorders with com-
mon features but also considerable heterogeneity in
biology and therapeutic responsiveness. This hetero-
geneity, together with the multiple forms of HCT
available, demands careful evaluation and planning to
best integrate HCT into the care of the individual
patient.
Standard Chemotherapy
Remission induction. For more than 2 decades,
standard induction chemotherapy for patients with
newly diagnosed AML age\60 years has been cytara-
bine 100 mg/m2 by continuous infusion for 7 days
combined with an anthracycline, such as daunorubicin
45-60 mg/m2/day for 3 days. Althouh many variations
on this general theme exist, none has been shown to be
clearly superior. For patients $60 years with an ac-
ceptable performance status, similar regimens can be
used, but for those with diminished performance
160 S. M. Davies et al.status, less intensive induction approaches may be
more appropriate. With standard induction chemo-
therapy, CR rates average approximately 75% to
80% for adults age\60 years, and roughly 50% for
adults $age 60 years. A number of known prognostic
factors greatly influence these CR rates, as will be dis-
cussed. It is, of course, axiomatic that entry onto a well-
conceived and designed clinical trial should be consid-
ered, if at all possible.
Postremission chemotherapy. If no postremis-
sion chemotherapy is given, patients will inevitable re-
lapse, usually within 4-6 months. Most contemporary
postremission chemotherapy regimens for younger
patients include multiple cycles of high-dose cytara-
bine, with or without additional agents. In the United
States, the most commonly used approach is 4 cycles of
high-dose cytarabine, 3 g/m2 every 12 hours on days 1,
3, and 5 [50]. Patients $60 years, particularly those
with comorbidities, are less able to tolerate such ag-
gressive chemotherapy and are more commonly
treated with several cycles of moderate-dose chemo-
therapy [51]. With commonly used chemotherapy reg-
imens, 35% to 40% of adults\60 years and 10% to
15% $60 years can expect to be alive in remission 5
years after diagnosis.
Chemotherapy for recurrent AML. The choice
of chemotherapy for recurrent AML is generally influ-
enced by patient age, health, initial therapy, and dura-
tion of first remission. Younger patients, and
particularly those with a longer first remission, are
usually treated with a regimen containing an anthracy-
cline plus high-dose cytarabine. For younger patients
with shorter remission durations, newer alternative
agents are generally recommended. Older individuals
and particularly those thought not to be candidates
for further aggressive therapy can benefit from a gem-
tuzumab-containing regimen. The likelihood of
achieving a second remission is heavily influenced by
the duration of first remission, among other factors.
CR2 rates as high as 75% are seen in patients relapsing
after a first remission of .2 years, but remission rates
of\25% are seen in those with a first remission lasting
\6 months [52]. Except for occasional patients with
favorable risk cytogenetics, the duration of second re-
mission is short, averaging 4-6 months in most studies.
HCT
Indications for HCT in patients age\60 years.
First remission. In 1979, Thomas et al [53] first
reported the outcome of allogeneic transplantation
from matched family member donors for a small series
of patients with AML in first CR. Currently, 37% of
these patients remain alive in remission 27 to 28 years
later. Since that original report, large numbers of
patients with AML in first remission have been trans-
planted; the CIBMTR reports 3174 patients receivingtransplants from HLA-matched siblings after high-
dose preparative regimens for AML in CR1 between
1998 and 2004 with a 3-year probability of survival
of 60% 6 1% [54].
A question of great practical importance is whether
patients with AML and a matched sibling should be
transplanted while in first remission or have transplant
delayed for use as salvage therapy. A large number of
trials have attempted to address this question by study-
ing a cohort of patients using a ‘‘genetic randomiza-
tion’’ in which patients with matched siblings are
allocated to allogeneic transplantation, whereas those
without serve as the chemotherapy controls. A recent
metaanalysis, which included all such studies con-
ducted between 1995 and 2003 that were written in
English, included an intent-to-treat analysis and pro-
vided survival data, identified 5 studies involving
3100 subjects [55]. For the entire cohort, there was
a statistically significant survival advantage associated
with the use of allogeneic transplantation. The benefit
was greatest for patents with unfavorable cytogenetics,
and lost for those with favorable risk cytogenetics.
Although this and similar studies provide interesting
information, they fall short of the mark of answering
the precise question for the patient with a matched sib-
ling, because such patients have an option of salvage
transplantation from their matched sibling, whereas
the ‘‘controls’’ in the genetic randomized studies do
not. With this caveat, the conclusion from the meta-
analysis is that there seems to be a survival advantage
for transplantation from a matched sibling for patients
with AML in CR1 with poor- or intermediate-risk
cytogenetics.
Recent data suggest that the intermediate-risk cat-
egory of AML might be divisible into subgroups with
poorer and more favorable prognoses. Schlenk et al
[56] recently reported that most patients with AML
with normal cytogenetics will have mutations in vari-
ous genes including NPM1 in 53%, FLT3-ITD in
31%, FLT-TKD in 11%, CEBPA in 14%, and
NRAS in 13%. In a prospective study in which patients
with AML in CR1 with normal cytogenetics were allo-
cated to an allogeneic transplant if they had a matched
sibling and/or to chemotherapy if no donor was avail-
able, a survival advantage for allogeneic transplanta-
tion was found, except in those with NPM11/
FLT3ITD2 AML [56].
For patients without matched family member do-
nors, the utility of autologous transplantation com-
pared to chemotherapy has been the subject of
a number of prospective randomized trials. A recent
metaanalysis considered all such studies that focused
on adult patients, were analyzed on an intent-to-treat
basis, and included greater than 75 patients in each
arm [57]. Six trials involving 4410 patients were
included. The combined results of these 6 trials indi-
cated that autologous transplantation modestly
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cluded in the metaanalysis were heterogeneous with
regard to treatment strategies, preparative regimens
and stem cell sources. Among the 6 studies, those
that showed the least evidence of benefit employed au-
tologous transplantation early after remission induc-
tion without much preceding consolidation therapy,
whereas those that applied transplantation after several
cycles of intensive consolidation seemed to show
a greater suggestion of benefit.
MUD transplantation offers another approach to
the treatment of AML in CR1. The CIBMTR re-
ported 41% 6 2% 3-year survival among 1066 adult
recipients of unrelated transplants [54]. Registry data
may be influenced by a number of factors, including,
on 1 hand, a likelihood that physicians only send
higher risk patients for unrelated transplants in CR1,
but on the other hand, that patients must remain in re-
mission for some months to actually be transplanted.
The sole prospective study so far reported is the Ger-
man 01/99 trial in which high-risk patients, as defined
by cytogenetics or having .5% blasts remaining in
marrow on day 15 of induction, were allocated to allo-
geneic transplantation if a matched sibling or MUD
could be found, or to autologous transplantation if
no donor was available [58]. At 4 years, survival was
68% among recipients of matched siblings transplants,
56% among unrelated donor transplant recipients, and
23% after autografting (P 5 .01).
Untreated first relapse or second remission.
Except for rare patients with favorable risk cytogenet-
ics and a long CR1, few patients with AML who re-
lapse after initial chemotherapy can be cured with
salvage chemotherapy. Thus, transplantation should
be considered for most patients who chose not to be
transplanted in first CR and subsequently relapse.
For such patients, an initial question is whether to pro-
ceed directly to transplant or to first attempt reinduc-
tion using chemotherapy. Often the answer is dictated
by the lack of an immediately available stem cell source
or access to a transplant facility. But in other cases,
a matched sibling or family member has already been
identified or autologous stem cells have been stored
while in first remission making transplantation in un-
treated first relapse a possibility. To date, there have
been only a limited number of studies describing the
outcome of matched sibling allogeneic transplantation
for AML in untreated first relapse. Studies from the
FHCRC report 3-year DFS of 28% among 126 pa-
tients [59]. A very similar result was reported by Brown
et al [60] from St. Louis. Data from the CIBMTR sug-
gest a 476 2% 5-year survival for patients over age 20
years receiving matched sibling allogeneic transplanta-
tion for AML in second remission [54]. Although at
first glance 47% appears superior to 28%, it should
be remembered that the likelihood of successful rein-
duction using chemotherapy is\50%. Thus, if 50%of patients with recurrent AML achieve second remis-
sion, and 50% of those are cured with allogeneic trans-
plantation, the overall salvage rate is about 25%,
a figure not superior to the 28% seen with allogeneic
transplantation in untreated first relapse. Of course,
considerable selection bias exists in both the patients
who make it through reinduction therapy and actually
get to transplant, as well as those who are stable
enough to make it to transplant without an urgent
need for reinduction chemotherapy.
There are very little data about the use of autolo-
gous transplantation in untreated first relapse. A single
study reported 8 of 38 patients (21%) alive in remission
several years after autografting in untreated first
relapse [61]. A much broader experience exists for
autografting for AML in CR2, where the CIBMTR re-
ports a 5-year survival of 40%6 3% [54]. Patients with
AML in CR2 also have an option for unrelated donor
transplantation. The CIBMTR data base reports
5-year survivals of 42% 6 2% for unrelated donor
transplants for AML in CR2 [54]. There are no pro-
spective randomized trials comparing the 2 ap-
proaches. There are, however, both single institution
and registry comparisons using matched-pair analyses
or proportional hazards regression in an attempt to
make adjustments for prognostic variables [62]. These
studies show, not surprisingly, decreased relapse rates
with unrelated donor transplants but decreased NRM
with autologous transplantation. These risks tend to
balance, and thus neither approach shows a clear ad-
vantage in these retrospective studies. Common sense
would argue that the increased disease control seen
with unrelated transplantation would favor this ap-
proach in younger patients and those with shorter first
remissions, whereas autologous transplantation might
be considered in older patients with longer first remis-
sions.
Refractory relapse. Lack of a consistent defini-
tion of ‘‘refractory relapse’’ complicates any discussion
of the topic. A simple and relatively unambiguous def-
inition includes only those patients who once achieved
a complete response, have since relapsed, and have
failed to achieve a subsequent CR or CRp with the
last reinduction attempt. The chance that such pa-
tients will benefit long term from an alternative che-
motherapy regimen was\1% in the M.D. Anderson
experience [63]. The results with transplantation are
likewise poor, with only 10% of such patients achiev-
ing 3-year DFS with matched sibling transplants, and
7% using MUD transplants [64,65]. Among those
transplanted in refractory relapse, results are margin-
ally better for patients with a lower leukemic burden
at the time of transplant, an observation that has led
to the practice of administering intensive chemother-
apy to clear circulating leukemic blasts prior to initiat-
ing the transplant preparative regimen. Whether such
an approach really improves the ultimate outcome of
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of ‘‘refractory relapse’’ exist; for example, Hiddemann
et al defined refractory relapse to include patients who
relapse within 12 months of first remission and those in
second and subsequent relapse, regardless of whether
they had received any attempts at reinduction. Not
surprisingly, transplant studies using this or similar
definitions of refractory relapse report modestly better
outcomes than those restricted to patients who failed
their last reinduction attempt.
Primary induction failure. In general, patients
with primary induction failure (defined as failure to
achieve an initial CR after at least 2 cycles of treatment)
have almost no hope for long-term survival using alter-
native chemotherapy strategies, yet several studies
have reported long-term DFS in approximately 20%
of such patients if transplanted from a matched sibling
[66,67]. Because of the time required to find an MUD,
very little data exist about unrelated transplants for pri-
mary induction failure, but the limited data available
demonstrate that cure is possible in 10% to 20% of pa-
tients. The potential of allogeneic transplantation to
save the lives of some patients who fail to achieve a first
remission emphasizes the importance of typing patient
and family members shortly after AML is diagnosed so
that valuable time is not lost in identifying donors
should remission induction attempts fail.
Indications for HCT in patient age 60 years or
greater. Autologous transplantation can be carried
out in patients age 60 years or greater with relative
safety, assuming the patient is otherwise reasonably
fit. However, there have been no prospective random-
ized trials comparing autologous transplantation to
chemotherapy for patients in this age group with
AML of any particular stage, and most guidelines, in-
cluding those of the National Comprehensive Cancer
Network (NCCN) do not recommend autologous
transplantation as a standard option for patients age
60 years or greater with AML in CR1.
Few studies of allogeneic transplantation for AML
in patients age 60 years or greater have been carried
out because of the perception that the use of high-
dose preparative regimens coupled with complications
because of allogenicity would prove overwhelmingly
toxic. With the popularization of RIC preparative reg-
imens, there has been renewed interest in the applica-
tion of allogeneic transplantation for this patient
population. A phase II trial using a preparative regi-
men of fludarabine and low-dose TBI in 122 patients,
median age 58, with AML reported a 2-year DFS of
44% for recipients of matched sibling transplant for
AML in CR1 and 63% after matched unrelated trans-
plantation [68]. The only prospective donor versus no
donor study so far published suggested an advantage
for allogeneic transplantation, with 4-year DFS of
54% in those with donors versus 30% in those treated
with chemotherapy [69].SUMMARY
Based on available data, all adults with AML under
age 60 years with matched siblings should be consid-
ered for allogeneic transplantation in first remission,
except for those with favorable risk cytogenetics and
possibly those whose disease has normal cytogenetics
and is FLT3/ITD negative and NPM1 positive. Pa-
tients with matched siblings not transplanted in first
remission should be followed closely so that transplan-
tation in early first relapse can be considered. Those
without matched siblings should receive a MUD trans-
plant in first CR if they have higher risk disease. All
others should receive standard chemotherapy and con-
sider a matched unrelated transplant or autologous
transplant, should they relapse. RIC allogeneic trans-
plantation using either a matched family member or
a MUD can be considered for patients age 60 years
or greater with AML in second or subsequent remis-
sion, or AML in first remission with intermediate or
high risk disease.
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